• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Alvotech

    2/14/23 5:13:01 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALVO alert in real time by email
    SC 13G 1 d428880dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.)*

     

     

    Alvotech

    (Name of Issuer)

    Ordinary Shares, with nominal value of $0.01 per share

    (Title of Class of Securities)

    L01800108

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


      1.    

      Names of Reporting Persons

     

      Oaktree Acquisition Holdings II, L.P.

      2.  

      Check The Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    Shares

      Beneficially  

    Owned By

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      10,916,667(1)

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      10,916,667(1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      10,916,667(1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.31%(2)

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    Represents (i) 6,250,000 ordinary shares and (ii) 4,666,667 ordinary shares issuable in connection with the exercise of private placement warrants to acquire ordinary shares on a one-for-one basis (“Warrants”).

    (2)

    Calculated based on (i) 248,649,505 ordinary shares outstanding as of July 14, 2022, as disclosed in the Issuer’s Form F-1/A filed September 14, 2022 and (ii) 4,666,667 ordinary shares issuable in connection with the exercise of the Warrants.


      1.    

      Names of Reporting Persons

     

      Oaktree Acquisition Holdings II GP, Ltd.

      2.  

      Check The Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    Shares

      Beneficially  

    Owned By

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      10,916,667(1)

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      10,916,667(1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      10,916,667(1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.31%(2)

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    (1)

    Represents (i) 6,250,000 ordinary shares and (ii) 4,666,667 ordinary shares issuable in connection with the exercise of the Warrants.

    (2)

    Calculated based on (i) 248,649,505 ordinary shares outstanding as of July 14, 2022, as disclosed in the Issuer’s Form F-1/A filed September 14, 2022 and (ii) 4,666,667 ordinary shares issuable in connection with the exercise of the Warrants.


      1.    

      Names of Reporting Persons

     

      Oaktree Capital Management, L.P.

      2.  

      Check The Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

      Beneficially  

    Owned By

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      13,596,829 (1)

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      13,596,829 (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      13,596,829 (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.37%(2)

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    Represents (i) 8,930,162 ordinary shares and (ii) 4,666,667 ordinary shares issuable in connection with the exercise of the Warrants.

    (2)

    Calculated based on (i) 248,649,505 ordinary shares outstanding as of July 14, 2022, as disclosed in the Issuer’s Form F-1/A filed September 14, 2022 and (ii) 4,666,667 ordinary shares issuable in connection with the exercise of the Warrants.


      1.    

      Names of Reporting Persons

     

      Oaktree Capital Management GP, LLC

      2.  

      Check The Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

      Beneficially  

    Owned By

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      13,596,829 (1)

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      13,596,829 (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      13,596,829 (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.37%(2)

    12.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    Represents (i) 8,930,162 ordinary shares and (ii) 4,666,667 ordinary shares issuable in connection with the exercise of the Warrants.

    (2)

    Calculated based on (i) 248,649,505 ordinary shares outstanding as of July 14, 2022, as disclosed in the Issuer’s Form F-1/A filed September 14, 2022 and (ii) 4,666,667 ordinary shares issuable in connection with the exercise of the Warrants.


      1.    

      Names of Reporting Persons

     

      Oaktree Specialty Lending Corporation

      2.  

      Check The Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      1,272,083 (1)

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      1,272,083 (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,272,083 (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      0.51%(2)

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    (1)

    Represents 1,272,083 ordinary shares.

    (2)

    Calculated based on 248,649,505 ordinary shares outstanding as of July 14, 2022, as disclosed in the Issuer’s Form F-1/A filed September 14, 2022.


      1.    

      Names of Reporting Persons

     

      Oaktree Fund Advisors, LLC

      2.  

      Check The Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      1,272,083(1)

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      1,272,083(1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,272,083(1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      0.51%(2)

    12.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    Represents 1,272,083 ordinary shares.

    (2)

    Calculated based on 248,649,505 ordinary shares outstanding as of July 14, 2022, as disclosed in the Issuer’s Form F-1/A filed September 14, 2022.


      1.    

      Names of Reporting Persons

     

      Oaktree Capital II, L.P.

      2.  

      Check The Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      1,272,083(1)

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      1,272,083(1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,272,083(1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      0.51%(2)

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    Represents 1,272,083 ordinary shares.

    (2)

    Calculated based on 248,649,505 ordinary shares outstanding as of July 14, 2022, as disclosed in the Issuer’s Form F-1/A filed September 14, 2022.


      1.    

      Names of Reporting Persons

     

      Oaktree Capital II GP LLC

      2.  

      Check The Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      1,272,083(1)

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      1,272,083(1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,272,083(1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      0.51%(2)

    12.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    Represents 1,272,083 ordinary shares.

    (2)

    Calculated based on 248,649,505 ordinary shares outstanding as of July 14, 2022, as disclosed in the Issuer’s Form F-1/A filed September 14, 2022.


      1.    

      Names of Reporting Persons

     

      Atlas OCM Holdings, LLC

      2.  

      Check The Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      14,868,912(1)

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      14,868,912(1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      14,868,912(1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.87%(2)

    12.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    Represents (i) 10,202,245 ordinary shares. and (ii) 4,666,667 ordinary shares issuable in connection with the exercise of the Warrants.

    (2)

    Calculated based on (i) 248,649,505 ordinary shares outstanding as of July 14, 2022, as disclosed in the Issuer’s Form F-1/A filed September 14, 2022 and (ii) 4,666,667 ordinary shares issuable in connection with the exercise of the Warrants.


      1.    

      Names of Reporting Persons

     

      Oaktree Capital Group Holdings GP, LLC

      2.  

      Check The Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      14,868,912(1)

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      14,868,912(1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      14,868,912(1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.87%(2)

    12.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    Represents (i) 10,202,245 ordinary shares and (ii) 4,666,667 ordinary shares issuable in connection with the exercise of the Warrants.

    (2)

    Calculated based on (i) 248,649,505 ordinary shares outstanding as of July 14, 2022, as disclosed in the Issuer’s Form F-1/A filed September 14, 2022 and (ii) 4,666,667 ordinary shares issuable in connection with the exercise of the Warrants.


      1.    

      Names of Reporting Persons

     

      Brookfield Asset Management ULC

      2.  

      Check The Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Ontario

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      0

       6.   

      Shared Voting Power

     

      14,868,912(1)

       7.   

      Sole Dispositive Power

     

      0

       8.   

      Shared Dispositive Power

     

      14,868,912(1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      14,868,912(1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.87%(2)

    12.  

      Type of Reporting Person (See Instructions)

     

      OO

     

    (1)

    Represents (i) 10,202,245 ordinary shares and (ii) 4,666,667 ordinary shares issuable in connection with the exercise of the Warrants.

    (2)

    Calculated based on (i) 248,649,505 ordinary shares outstanding as of July 14, 2022, as disclosed in the Issuer’s Form F-1/A filed September 14, 2022 and (ii) 4,666,667 ordinary shares issuable in connection with the exercise of the Warrants.


    Item 1(a).    Name of Issuer:
       Alvotech (the “Issuer”)
    Item 1(b).    Address of Issuer’s Principal Executive Offices:
      

    9, Rue de Bitbourg,

    Luxembourg, Luxembourg L-1273

    Item 2(a).    Names of Persons Filing:
      

    This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1(k)(1) promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Act:

     

    (i)   Oaktree Acquisition Holdings II, L.P. (“Acqusition Holdings”)

     

    (ii)   Oaktree Acquisition Holdings II GP, Ltd. (“Acquisition Holdings GP”)

     

    (iii)    Oaktree Capital Management, L.P.(“Capital Management”)

     

    (iv)  Oaktree Capital Management GP, LLC (“Capital Management GP”)

     

    (v)    Oaktree Specialty Lending Corporation (“Specialty Lending”)

     

    (vi)  Oaktree Fund Advisors, LLC (“Fund Advisors”)

     

    (vii)   Oaktree Capital II, L.P. (“Capital II”)

     

    (viii)   Oaktree Capital II GP LLC (“Capital II GP”)

     

    (ix)  Atlas OCM Holdings, LLC (“Atlas”)

     

    (x)    Oaktree Capital Group Holdings GP, LLC (“OCGH LLC”)

     

    (xi)  Brookfield Asset Management, ULC (“Brookfield”)

     

    each of which is referred to as a “Reporting Person,” or collectively, the “Reporting Persons.”

    Item 2(b).    Address of the Principal Business Office or, if None, Residence:
      

    c/o Oaktree Capital Management, L.P.,

    333 South Grand Ave, 28th Floor,

    Los Angeles, CA, 90071

     

    c/o Brookfield Asset Management, ULC

    Brookfield Place, Suite 100.

    181 Bay Street,

    PO Box 762,

    Toronto, Ontario, Canada M5J 2T3

    Item 2(c).    Citizenship:
       See responses to Item 4 on each cover page.
    Item 2(d).    Title of Class of Securities:
       Ordinary Shares, with nominal value of $0.01 per share
    Item 2(e).    CUSIP Number:
       L01800108
    Item 3.    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a(n):
       Not Applicable.


    Item 4.   

    Ownership.

     

    (a)   Amount beneficially owned:

     

    See responses to Item 9 on each cover page.

     

    (b)  Percent of Class:

     

    See responses to Item 11 on each cover page.

     

    (c)   Number of shares as to which the Reporting Person has:

     

    (i) Sole power to vote or to direct the vote:

     

    See responses to Item 5 on each cover page.

     

    (ii)  Shared power to vote or to direct the vote:

     

    See responses to Item 6 on each cover page.

     

    (iii)  Sole power to dispose or to direct the disposition of:

     

    See responses to Item 7 on each cover page.

     

    (iv) Shared power to dispose or to direct the disposition of:

     

    See responses to Item 8 on each cover page.

     

    Each of the percentages referenced in this Statement are calculated based on 248,649,505 ordinary shares outstanding as of July 14, 2022, as disclosed in the Issuer’s Form F-1/A filed September 14, 2022, as increased by 4,666,667 ordinary shares issuable upon exercise of the Warrants held by the Reporting Persons (the “Calculation Method”).

     

    The reported securities are held as follows:

     

    •  Acquisition Holdings directly holds 6,250,000 ordinary shares, inclusive of shares subject to certain restrictions and earnout terms and 4,666,667 Warrants, together representing 4.31% of shares outstanding based on the Calculation Method. As the general partner of Acquisition Holdings, Acquisition Holdings GP may be deemed to beneficially own such ordinary shares and warrants.

     

    •  Specialty Lending directly hold 1,272,083 ordinary shares, inclusive of shares subject to certain earnout terms, representing 0.51% of shares outstanding based on the Calculation Method.

     

    •  Certain separately managed accounts managed by Capital Management (“SMAs”) directly hold 2,680,162 ordinary shares, inclusive of shares subject to certain earnout, and Capital Management as the director of Acquisition Holdings GP may also be deemed to beneficially own the 6,250,000 ordinary shares and 4,666,667 Warrants held by Acquisition Holdings. As the general partner of Capital Management, Capital Management GP may be deemed to beneficially own the ordinary shares directly held by the SMAs and by Acquisition Holdings, together representing 5.37% of the shares outstanding based on the Calculation Method.

     

    •  Fund Advisors is the investment advisor to Specialty Lending and may be deemed to beneficially own the 1,272,083 ordinary shares directly held by Specialty Lending, representing 0.51% of the shares outstanding based on the Calculation Method. Capital II, as the managing member of Fund Advisors, and Capital II GP, as the general partner of Capital II, may also be deemed to own such securities.


      

    •  `Atlas is the sole managing member of Capital Management GP and the managing member of Capital II GP and may be deemed to beneficially own the 10,202,245 ordinary shares and 4,666,667 Warrants directly held by Acquisition Holdings, Specialty Lending, and the SMAs, collectively representing 5.87% of the shares outstanding based on the Calculation Method.

      

    •  Brookfield and OCGH LLC each, in its capacity as the indirect owner of Atlas has the ability to appoint and remove certain directors of Atlas and, as such, may indirectly control the decisions of Atlas regarding the vote and disposition of securities directly or indirectly held by Atlas. As such each of Brookfield and OCGH LLC may beneficially own the 10,202,245 ordinary shares and 4,666,667 Warrants beneficially owned by Atlas, representing 5.87% of the shares outstanding based on the Calculation Method.

     

    The filing of this Statement shall not be construed as an admission that the Reporting Person are, for the purpose of Section 13(d) or 13(g) of the Exchange Act, members of a “group” or the beneficial owner of any securities covered by this Statement.

    Item 5.    Ownership of Five Percent or Less of a Class.
       Not Applicable.
    Item 6.    Ownership of More than Five Percent on Behalf of Another Person.
       Not Applicable.
    Item 7.    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       Not Applicable.
    Item 8.    Identification and Classification of Members of the Group.
       Not Applicable.
    Item 9.    Notice of Dissolution of Group.
       Not Applicable.
    Item 10.    Certification.
       Not Applicable.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:     February 14, 2023

     

    Oaktree Acquisition Holdings II, L.P.
    By: Oaktree Acquisition Holdings II GP, Ltd.
    Its: General Partner
    By:  

    /s/ Henry E. Orren

    Name: Henry E. Orren
    Title: Authorized Signatory
    Oaktree Acquisition Holdings II GP, Ltd.
    By: Oaktree Capital Management, L.P.
    Its: Director
    By:  

    /s/ Henry E. Orren

    Name: Henry E. Orren
    Title: Senior Vice President
    Oaktree Capital Management, L.P.
    By: Oaktree Capital Management GP, LLC
    Its: General Partner
    By:    

    /s/ Henry E. Orren

    Name: Henry E. Orren
    Title: Authorized Signatory
    Oaktree Capital Management GP, LLC
    By: Atlas OCM Holdings, LLC
    Its: Sole Managing Member
    By:    

    /s/ Henry E. Orren

    Name: Henry E. Orren
    Title: Senior Vice President
    Oaktree Specialty Lending Corporation
    By: Oaktree Fund Advisors, LLC
    Its: Investment Advisor
    By:    

    /s/ Henry E. Orren

    Name: Henry E. Orren
    Title: Authorized Signatory
    Oaktree Fund Advisors, LLC
    By: Oaktree Capital II, L.P.
    Its: Managing Member
    By:    

    /s/ Henry E. Orren

    Name: Henry E. Orren
    Title: Authorized Signatory


    Oaktree Capital II, L.P.
    By: Oaktree Capital II GP LLC
    Its: General Partner
    By:    

    /s/ Henry E. Orren

    Name: Henry E. Orren
    Title: Authorized Signatory
    Oaktree Capital II GP LLC
    By: Atlas OCM Holdings, LLC
    Its: Managing Member
    By:    

    /s/ Henry E. Orren

    Name: Henry E. Orren
    Title: Senior Vice President
    Atlas OCM Holdings, LLC
    By:    

    /s/ Henry E. Orren

    Name: Henry E. Orren
    Title: Senior Vice President
    Oaktree Capital Group Holdings GP, LLC
    By:    

    /s/ Henry E. Orren

    Name: Henry E. Orren
    Title: Authorized Signatory
    Brookfield Asset Management, ULC
    By:    

    /s/ Kathy Sarpash

    Name: Kathy Sarpash
    Title: Senior Vice President Legal & Regulatory


    EXHIBIT LIST

    Get the next $ALVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALVO

    DatePrice TargetRatingAnalyst
    2/14/2025$18.00Buy
    UBS
    1/29/2024$10.00 → $17.00Equal Weight → Overweight
    Barclays
    10/20/2023$5.00 → $10.00Sell → Neutral
    Citigroup
    9/21/2023$10.00Equal Weight
    Barclays
    9/7/2022$10.00Equal-Weight
    Morgan Stanley
    9/6/2022$12.00 → $5.00Buy → Sell
    Citigroup
    More analyst ratings

    $ALVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada

      REYKJAVIK, Iceland, May 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the BofA Securities Healthcare Conference 2025, which will be held in Las Vegas, Nevada, May 13-15, 2025. Members of the management team will host one-on-one meetings at the conference. Alvotech will also be participating in a fireside chat on Wednesday, May 14, 2025, at 11:40 am-12:10 pm EDT (15:40-16:10 GMT / 17:40-18:10 CET). A live audio webcast of the fireside chat will also be available to the general public and can be accessed at https://investors.a

      5/9/25 8:00:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

      Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increaseProduct Revenues in the first in the first quarter of 2025 reached $109.9 million, compared to $12.4 million in the same period last year, representing a 786% increaseAdjusted EBITDA in the first quarter of 2025 was $20.5 million compared to negative $38.4 million in 2023Full year guidance increased to $600-$700 million in top line revenue and $200-280 million adjusted EBITDA, following acquisition of proposed biosimilar to CimziaAlvotech will conduct a business update conference call and live webcast on Thursday May 8, 2025, at 8:00 am ET (1

      5/7/25 4:45:00 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025

      REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ:ALVO) (the "Company") a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of potential tariffs on imported pharmaceuticals to the United States. Alvotech expects that potential U.S. tariffs on imported pharmaceuticals should have minimal impact on the Company's product revenues in 2025. Alvotech manufactures its biosimilars in Iceland, a country which currently faces the minimum tariff of 10% on goods imported to the U.S. A 10% tariff on pharmaceuticals would raise the cost of biosimilars from Alvotech

      5/7/25 5:00:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVO
    Financials

    Live finance-specific insights

    See more
    • Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

      Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increaseProduct Revenues in the first in the first quarter of 2025 reached $109.9 million, compared to $12.4 million in the same period last year, representing a 786% increaseAdjusted EBITDA in the first quarter of 2025 was $20.5 million compared to negative $38.4 million in 2023Full year guidance increased to $600-$700 million in top line revenue and $200-280 million adjusted EBITDA, following acquisition of proposed biosimilar to CimziaAlvotech will conduct a business update conference call and live webcast on Thursday May 8, 2025, at 8:00 am ET (1

      5/7/25 4:45:00 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT

      REYKJAVIK, Iceland, May 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first quarter ended March 31, 2025, after U.S. markets close on Wednesday, May 7, 2025. Alvotech will also conduct a conference call with analysts to present the financial results and recent business highlights on Thursday, May 8, 2025, at 8:00 am EDT (12:00 noon GMT, 14:00 CET).   Live audio of the conference call will be webcast and available to members of the news media, investors, and the general public. Information on how

      5/2/25 8:30:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech Reports Record Results for 2024 and Provides Business Update

      Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in 2024 was $108.3 million compared to negative $291 million in 2023Submissions in major global markets were made in 2024 for three new proposed biosimilars. All applications have been subsequently accepted by the relevant regulatory authorities.Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm GMT). REYKJAVIK, Iceland, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, or the "Company")), a global biotech company

      3/26/25 6:34:30 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVO
    SEC Filings

    See more
    • SEC Form 6-K filed by Alvotech

      6-K - Alvotech (0001898416) (Filer)

      5/9/25 12:30:47 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Alvotech

      6-K - Alvotech (0001898416) (Filer)

      5/8/25 6:00:33 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Alvotech

      6-K - Alvotech (0001898416) (Filer)

      5/7/25 11:58:42 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for SELARSDI issued to ALVOTECH USA INC

      Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

      10/21/24 10:44:05 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SELARSDI issued to ALVOTECH USA INC

      Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

      10/21/24 2:59:28 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for SELARSDI issued to ALVOTECH USA INC

      Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

      10/21/24 2:59:28 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Alvotech

      SC 13G/A - Alvotech (0001898416) (Subject)

      11/6/24 1:51:59 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Alvotech

      SC 13D/A - Alvotech (0001898416) (Subject)

      7/3/24 5:31:12 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Alvotech (Amendment)

      SC 13G/A - Alvotech (0001898416) (Subject)

      2/14/24 12:14:38 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Alvotech with a new price target

      UBS initiated coverage of Alvotech with a rating of Buy and set a new price target of $18.00

      2/14/25 9:00:38 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech upgraded by Barclays with a new price target

      Barclays upgraded Alvotech from Equal Weight to Overweight and set a new price target of $17.00 from $10.00 previously

      1/29/24 7:03:36 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech upgraded by Citigroup with a new price target

      Citigroup upgraded Alvotech from Sell to Neutral and set a new price target of $10.00 from $5.00 previously

      10/20/23 7:21:31 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ALVO
    Leadership Updates

    Live Leadership Updates

    See more
    • Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

      REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, or the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer. A medical doctor by training, Dr. Prasad has 25 years' experience in the pharmaceutical industry, first as a consultant and subsequently as a financial and equities analyst focused on the specialty pharma and healthcare sectors. He was most recently a director and highly ranked equities analyst at Barclays, covering US specialty pharma and with Alvotech in his portfolio. He served previously

      3/27/25 4:30:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

      REYKJAVIK, Iceland and STOCKHOLM, March 20, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB's ("Xbrane") R&D operations and a biosimilar candidate (the "Acquisition"), further expanding Alvotech's development capabilities, and establishing a footprint in the Swedish life science sector. The Acquisition includes Xbrane's R&D operations based in Campus Solna, at the Karolinska Institute outside Stockholm, Sweden, as well as the biosimilar candidate XB003, referencing Cimzia® (certolizumab pegol). Xbrane retains other

      3/20/25 3:00:00 AM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alvotech Appoints Interim Chief Quality Officer

      REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate leadership team as interim Chief Quality Officer. Christina succeeds Sandra Casaca, who is leaving the company as a part of other organizational changes. Christina Siniscalchi has for over ten years served in senior quality positions for Alvogen and its manufacturing site in Norwich, NY, most recently as Alvogen's Chief Quality Officer. "We thank Sandra for her valuable contribution to Alvotech, as she successfully steered ou

      2/29/24 4:05:00 PM ET
      $ALVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care